The biggest increase in 2-year survival associated with Medicaid expansion was among patients with stage III disease, with a ...

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...

Monopar Therapeutics (MNPR) surges 20% pre-market after entering exclusive agreement with Alexion, AstraZeneca for Wilson ...

AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the me | AstraZeneca has rolled out a ...

Monopar Therapeutics (MNPR) announced that it has entered into an agreement with Alexion, AstraZeneca (AZN) Rare Disease for an exclusive ...

Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune ...

The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated ...

Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

Monopar Therapeutics shares rose after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion. Shares of the Wilmette, Ill., ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...